¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"alpha orientation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® alpha particles ÇÑ±Û ¾ËÆÄÀÔÀÚ
¼³¸í   
  ¿øÀÚ¿¡ Á¤»óº¸´Ù °ú´Ù, °ú¼ÒÇÑ Áß¼ºÀÚ³ª ¾çÀÚ¸¦ °¡Áö°í Àִ °æ¿ì¿¡ ¿øÀÚ°¡ ¾ÈÁ¤µÇ±â À§Çؼ­ ºØ±«°¡ »ý±ä´Ù. ÀÌ·± ºØ±«¿¡´Â ´ÙÀ½°ú °°Àº 3°¡Áö ¹æ¹ýÀÌ ÀÖ´Ù. ¾ËÆÄ£­ºØ±«´Â ¾ËÆÄÀÔÀÚ¸¦ ¹æÃâÇÏ¿© ¾ÈÁ¤µÇ´Â ¹ý, Áï ¿øÀÚ¹øÈ£´Â 2¾¿ °¨¼ÒÇϰí Áú·®¼ö´Â 4¾¿ °¨¼ÒÇÑ´Ù. ¾ËÆÄÀÔÀÚ¶õ ¾ËÆÄºØ±«¿¡ ÀÇÇØ¼­ »ý±â´Â Çï·ýÀÇ ÇÙ°ú °°Àº ÀÔÀÚ¸¦ ¸»ÇÑ´Ù.
  
  
¿µ¹® alpha-fetoprotein ÇÑ±Û ¾ËÆÄžƴܹé
¼³¸í   
  Å¾ÆÀÇ °£Á¶Á÷À̳ª ¼ÒÈ­±â°ü¿¡¼­ ¸¸µé¾îÁö´Â ´Ü¹éÁú. Å¾Ʊ⳪ ÀÓ»êºÎ¿¡¼­ Á¤»óÀûÀ¸·Î Á¸ÀçÇÑ´Ù. ±×·¯³ª °£¾Ï¼¼Æ÷³ª »ý½Ä¼¼Æ÷¿¡ °ü·ÃµÈ Á¾¾ç¿¡¼­µµ ¸¸µé¾îÁ® ÀÌ·± Áúº´ÀÌ Á¸ÀçÇÒ ¶§¿¡´Â ÀÓ»êºÎ³ª Å¾ư¡ ¾Æ´Ï´õ¶óµµ Á¶Á÷À̳ª Ç÷¾×¿¡ ³ªÅ¸³ª°Ô µÈ´Ù. ÀÓ»óÀûÀ¸·Î´Â °£¾ÏÀ̳ª »ý½Ä¼¼Æ÷ Á¾¾çÀÇ ¹ß°ß°ú Ä¡·áÈ¿°ú ÆÇÁ¤¿¡ ÀÌ¿ëµÇ°í, ¶Ç ÀӽŠ16~18ÁÖ¿¡ »ê¸ðÀÇ Ç÷¾×¿¡¼­ À̴ܹéÁúÀÇ ¾çÀ» ÃøÁ¤ÇÏ¿© Å¾ÆÀÇ ºñÁ¤»óÀûÀΠ¹ß´ÞÀ» ¹ß°ßÇÒ ¼ö ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • double orientation
    ÀÌÁßÁö³²·Â
  • egosyntonic sexual orientation
    ÀھƵ¿Á¶Àû¼ºÁö³²·Â
  • molecular orientation
    ºÐÀÚ¹èÇâ
  • orientation
    1. Áö³²·Â, ¹æÇâ°¨ 2. ±æÀâÀÌ
  • reversed orientation
    µµÂøÁö³²·Â, °Å²ÜÁö³²·Â
  • temporal orientation
    ½Ã°£°áÁ¤
  • alpha emitter
    ¾ËÆÄ¹æÃâü
  • alpha error
    ¾ËÆÄ¿À·ù, Á¦1Çü¿À·ù
  • alpha granule
    ¾ËÆÄ°ú¸³
  • alpha hemolysis
    ¾ËÆÄ¿ëÇ÷
  • alpha motor neuron
    ¾ËÆÄ¿îµ¿½Å°æ¼¼Æ÷
  • alpha ray
    ¾ËÆÄ¼±
  • alpha wave
    ¾ËÆÄÆÄ
  • alpha-adrenergics
    ¾ËÆÄ¾Æµå·¹³¯¸°¼º¾à
  • alpha-chymotrypsin
    ¾ËÆÄŰ¸ðÆ®¸³½Å
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • orientation disturbance
    Áö³²·ÂÀå¾Ö, ¹æÇâ°¨Àå¾Ö
  • orientation
    1.Áö³²·Â, ¹æÇâ°¨, 2.±æÀâÀÌ
  • alpha-interferon
    ¾ËÆÄÀÎÅÍÆä·Ð
  • alpha-adrenergics
    ¾ËÆÄ¾Æµå·¹³¯¸°¼º¾à
  • alpha-fetoprotein
    ¾ËÆÄžƴܹé
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • double orientation
    ÀÌÁßÁö³²·Â
  • orientation disturbance
    Áö³²·ÂÀå¾Ö, ¹æÇâ°¨°¢Àå¾Ö
  • egosyntonic sexual orientation
    ÀھƵ¿Á¶Àû¼ºÁö³²·Â
  • molecular orientation
    ºÐÀÚ¹èÇâ
  • orientation
    Áö³²·Â
  • reversed orientation
    µµÂøÁö³²·Â, °Å²ÜÁö³²·Â
  • temporal orientation
    ½Ã°£°áÁ¤
  • alpha-chymotrypsin
    ¾ËÆÄÄ«ÀÌ¸ðÆ®¸³½Å
  • alpha-fetoprotein
    ¾ËÆÄžƴܹé
  • alpha-interferon
    ¾ËÆÄÀÎÅÍÆä·Ð
  • alpha-lipoproteinemia
    ¾ËÆÄÁö¹æ´Ü¹éÇ÷Áõ
  • alpha emitter
    ¾ËÆÄ¹æÃâ±â
  • alpha error
    Á¦ÀÏÁ¾¿À·ù
  • alpha granule
    ¾ËÆÄ°ú¸³
  • alpha hemolysis
    ¾ËÆÄ¿ëÇ÷, ºÒ¿ÏÀü¿ëÇ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • 17-alpha-hydroxycorticosteroid
    17-¾ËÆÄ-È÷µå·Ï½ÃÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å
  • 17-alpha-hydroxyprogesterone
    17-¾ËÆÄ-È÷µå·Ï½ÃÇÁ·Î°Ô½ºÅ×·Ð
  • alpha behavior
    ¾ËÆÄÇàÀ§
  • alpha blocking
    ¾ËÆÄÂ÷´Ü
  • alpha cell
    ¾ËÆÄ¼¼Æ÷
  • alpha cell
    ¾ËÆÄ¼¼Æ÷(¡­á¬øà)
  • alpha cell glucagon cell
    ¾ËÆÄ¼¼Æ÷ ±Û·çÄ«°ï¼¼Æ÷
  • alpha cell tumor
    ¾ËÆÄ ¼¼Æ÷Á¾(¡­á¬øàðþ)
  • alpha chain disease
    ¾ËÆÄ¼âº´(¡­áðÜ»).
  • alpha chain disease
    ¾ËÆÄ¼âÁúȯ
  • alpha cradle
    ¾ËÆÄ¹Þħ´ë
  • alpha decay
    ¾ËÆÄºØ±«
  • alpha emitter
    ¾ËÆÄ¹æ»çü, ¾ËÆÄ¹æÃâü
  • alpha fetoprotein =AFP
    ¾ËÆÄžƴܹé(¡­÷Ãä®Ó±ÛÜ).
  • alpha fiber
    ¾ËÆÄ(½Å°æ)¼¶À¯
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • orientation, double (double orientation)
    ÀÌÁßÁö³²·Â.
  • orientation, reversed (reversed orientation)
    µµÂøÁö³²·Â.
  • audiometry, conditioned orientation reflex
    Á¶°Ç¹Ý»çû·Â°Ë»ç
  • double orientation
    ÀÌÁßÁöÇâ.
  • false orientation
    ¹æÇâ¿ÀÀÎ
  • investigating reflex =orientation r.
    Ž»ö¹Ý»ç(÷®ßãÚãÞÒ).
  • molecular orientation
    ºÐÀÚ¹èÇâ(¡­ÛÕú¾).
  • orientation
    (¹æÇâ)Á¤À§(Û°ú¾ïÒêÈ), Áö³²·Â(ò¦Ñõæ³), ¹èÇâ(ÛÕú¾), ¿¹ºñ±³À°(çã ÝáÎçëÀ).
  • orientation
    Âø»ó¹æÇâ
  • orientation column
    ¹æÀ§(ÇÇÁú)±âµÕ
  • orientation disturbance
    ¹æÇâ°¨°¢Àå¾Ö.
  • orientation plate
    ±âÁØÆÇ(˻̡̬).
  • orientation plate for compensating curve
    ±³ÇÕ¸¸°î±âÁØÆÇ(ÎáùêØ¶ÍØÐññÞ÷ù).
  • orientation plate for lateral compensating curve
    Ãø¹æ¸¸°î±âÁØÆÇ(ö°Û°Ø¶ÍØ ÐññÞ÷ù).
  • orientation reflex
    ÁöÇâ¹Ý»ç(ò¦ú¾ÚãÞÒ), ¹æÇâÁ¤À§¹Ý»ç.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Alpha cell [Glucagon cell]
    ¾ËÆÄ¼¼Æ÷ [±Û·çÄ«°ï¼¼Æ÷]
    [¿¾ ¿ë¾î] ¾ËÆÄ¼¼Æ÷
  • Orientation
    Âø»ó¹æÇâ
    [¿¾ ¿ë¾î] ¹æÇâ¼³Á¤
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • alpha orientation
    ¾ËÆÄ¿À¸®¿£Å×À̼Ç
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • beta orientation
    º£Å¸ ¹èÀ§(ÛÕêÈ)
  • n orientation
    n ¹èÇâ(ÛÕú¾)
  • orientation effect
    Á¤À§ È¿°ú(ïÒêÈüùÍý)
  • u orientation
    u ¹èÇâ(ÛÕú¾)
  • alpha adrenergic receptor
    ¾ËÆÄ¾Æµå·¹³ª¸°ÀÛµ¿¼º(íÂÔÑàõ) ¼ö¿ëü(áôé»ô÷)
  • alpha amanitin
    ¾ËÆÄ¾Æ¸¶´Ïƾ
  • alpha amino acid
    ¾ËÆÄ¾Æ¹Ì³ë»ê(ß«)
  • alpha blocker
    ¾ËÆÄÂ÷´ÜÁ¦(ó´Ó¨ð¥)
  • alpha bungarotoxin
    ¾ËÆÄºÐ°¡·ÎÅå½Å
  • alpha fraction
    ¾ËÆÄºÐȹ(ÝÂüñ)
  • alpha receptor
    ¾ËÆÄ¼ö¿ëü(áôé»ô÷)
  • alpha tocopherol
    ¾ËÆÄÅäÄÚÆä·Ñ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • orientation disturbance
    ¹æÇâ°¨°¢Àå¾Ö
  • alpha
    ¾ËÆÄ
  • alpha fetoprotein
    ¾ËÆÄžƴܹé
  • alpha ray
    ¾ËÆÄ¼±
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
alpha-GLUC alpha-glucosidase
AOA American Osteopathic Association; Administration on Aging; Alpha Omega Alpha Honor Society; American...
PAL pathology laboratory; peptidyl-alpha-hydroxyglycine alpha-amidating lysine phase alteration plane; p...
AO abdominal aorta; achievement orientation; acid output; acridine orange; ankle orthosis; anodal openi...
COAT Children's Orientation and Amnesia Test
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
GOAT Galveston Orientation and Amnesia Test
POI Personal Orientation Inventory
RO REality Orientation
3 alpha-diol alpha-Androstan-3 alpha, 17 beta-diol
1 alpha(OH)D3 1 alpha hydroxyvitamin D3
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • double orientation
    ÀÌÁß ÁöÇâ
  • longitudinal orientation
    Á¾ ¹æÇâ
    ½Åü ¶Ç´Â Àå±âÀÇ ÀåÃà¿¡ µû¶ó¼­ ¹è¿­.
  • molecular orientation
    ºÐÀÚ ¹èÇâ
  • orientation
    ¹è¿­, Áö³²·Â, ¿¹ºñ ±³À°, Á¤À§, ¹æÇâ Á¤À§, ¹èÇâ
    °ø°£, ½Ã°£, »ç¶÷¿¡ ´ëÇÑ ÀÚ±âÀ§Ä¡, ȯ°æÀÇ °áÁ¤.
  • orientation plate for lateral compensating curve
    Ãø¹æ ¸¸°î ±âÁØÆÇ
    ÃÑ ÀÇÄ¡ÀÇ ÀΰøÄ¡ ¹è¿­ÀÇ °æ¿ì ±³Çձ⠻󿡼­ Àû´çÇÑ Á¶Àý ¸¸°îÀ» ÁÙ ¶§ »ç¿ëÇÏ´Â ±âÁØÆÇ. MonsonÀº Á¶Àý ¸¸°îÀÇ ¹Ý°æÀ» 10§¯·Î Çϰí ÀÖ´Ù. ¾ç ÁßÀýÄ¡¿Í Á¦ 2´ë±¸Ä¡ ¿ø½É ÇùÃø ±³µÎ¸¸À» ±³ÇÕÁ¦»ó¸é¿¡ Á¢Ã˽Ã۰í
  • orientation test
    ¼ÒÀç½Ä ½ÃÇè
    ÇǰËÀÚ°¡ ½Ã°¢, ¿äÀÏ, ¿ù, ³â, Àå¼Ò¸¦ ¹Ù¸£°Ô Ç¥¸íÇÒ ¼ö ÀÖ´ÂÁö ¾ø´ÂÁö¸¦ ¾Ë¾Æº¸´Â ½ÃÇè.
  • A alpha
    A ¾ËÆÄ, A ¾ËÆÄ ½Å°æ ¼¶À¯
  • A alpha primary afferent
    A ¾ËÆÄ ÀÏÂ÷ ±¸½É ½Å°æ
    ±Ù¹æÃß ³»ÀÇ ±Ù ¼¶À¯¿¡ Á¸ÀçÇÏ´Â °¨°¢½Å°æÀÇ Çϳª·Î ¥°a °¨°¢ ½Å°æÀ̶ó°íµµ ÇÑ´Ù. Á÷°æÀº 22§­, Àüµµ ¼Óµµ´Â 120§½ÀÌ´Ù.
  • A-alpha mechanoreceptor
    A ¾ËÆÄ ±â°è ¼ö¿ë±â
    ±Ù ¹æÃß¿Í °ñÁö °Ç ±â°ü¿¡ Á¸ÀçÇÑ´Ù.
  • alpha
    ¥á
    chain
  • alpha 1-adrenergic blocker
    ¾ËÆÄ 1-¾Æµå·¹³¯¸°¼º Â÷´Ü
  • alpha 2 agonist clonidine
    ¾ËÆÄ 2 ÀÛµ¿ Ŭ·Î´Ïµò
  • alpha 2 binding
    ¾ËÆÄ 2 °áÇÕ
  • alpha adrenergic antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸° ±æÇ×Á¦
  • alpha amylose
    ¾ËÆÄ-¾Æ¹Ð·Î½º
    °ÅÀÇ ¾Æ¹Ð·Î½ºÀÎ ÀüºÐÀÇ ÁÖ¼ººÐÀ¸·Î¼­, ±Û·çÄÚ½º°¡ a-1,4 °áÇÕÀ¸·Î Á÷¼â»ó °áÇÕÇÑ °Í.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
orientation <psychology> Awareness of one's environment, with reference to person, time and place.
(18 Nov 1997)
orientation chamber <cell culture> Chamber designed by Zigmond in which to test the ability of cells (neutrophils) to orient in a gradient of chemoattractant. The chamber is similar to a haemocytometer, but with a depth of only ca. 20m. The gradient is set up by diffusion from one well to the other and the orientation of cells towards the well containing chemoattractant is scored on the basis of their morphology or by filming their movement.
(18 Nov 1997)
alpha, alpha-phosphotrehalase <enzyme> Forms glucose plus glucose-6-phosphate
Registry number: EC 3.2.1.93
Synonym: trehalose-6-phosphate hydrolase, phospho-alpha(1,1)glucosidase, trea gene product, trec gene product
(26 Jun 1999)
alpha,alpha-trehalose phosphorylase <enzyme> Chemical name: alpha-d-glucopyranosyl-alpha-d-glucopyranose orthophosphate glucosyltransferase
Registry number: EC 2.4.1.64
Synonym: trehalose phosphorylase
(26 Jun 1999)
alpha-dextrin endo-1,6-alpha-glucosidase <enzyme> An enzyme with action similar to that of isoamylase; it cleaves 1,6-alpha-glucosidic linkages in pullalan, amylopectin, and glycogen, and in alpha-and beta-amylase limit-dextrins of amylopectin and glycogen.
Compare: isoamylase.
Synonym: limit dextrinase, pullulanase, R enzyme.
(05 Mar 2000)
alpha-hydroxymethyl-alpha'-(N-acetylaminomethylene)succinic acid hydrolase <enzyme> Involved in degradation of vitamin b6; forms acetic acid plus ammonia plus carbon dioxide plus alpha-hydroxymethyl-succinic monoaldehyde
Registry number: EC 3.5.1.-
Synonym: compound b hydrolase
(26 Jun 1999)
cholesterol-5 alpha,6 alpha-epoxide hydrase <enzyme> Aspect of epoxide hydrolase, EC 3.3.2.3
Pharmacological action: carcinogen
Registry number: EC 3.3.2.-
Synonym: cholesterol epoxide hydrase, cholesterol epoxide hydrolase
(26 Jun 1999)
CMP-acetylneuraminate-alpha-N-acetylneuramide alpha-2,8-sialyltransferase <enzyme> Forms ganglioside gd3
Registry number: EC 2.4.99.8
Synonym: cmp-n-acetylneuraminate-gm3 sialyltransferase, gm3-sialosyltransferase, gd3 synthase, gd3-synthase, cmp-n-acetylneuraminate-(n-acetylneuraminyl)-d-galactosyl-d-glucosylceramide sialyltransferase, sialyltransferase II, st II, g(m3) alpha-2,8-sialyltransferase, st8sia I, stii enzyme, stiii enzyme, gt3 synthase
(26 Jun 1999)
CMP-N-acetylneuraminate-alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase <enzyme> Enzyme from foetal calf liver; forms branched tetrasaccharide, neuac-alpha2-3gal-beta1-3(neuac-alpha2-6)galnac of fetuin
Registry number: EC 2.4.99.3
Synonym: cmp-aag-sialyltransferase, st6galnaci, galnac 2,6-sialyltransferase
(26 Jun 1999)
NAD 3 alpha-hydroxy-5 alpha-pregnan-20-one-oxidoreductase <enzyme> From rat liver microsomes
Registry number: EC 1.1.1.-
Synonym: nad-3-hp-20-oor
(26 Jun 1999)
1,4-alpha-d-glucan 6-alpha-d-glucosyltransferase A glucosyltransferase that transfers an alpha-glucosyl residue in a 1,4-alpha-glucan to the primary hydroxyl group of glucose in a 1,4-alpha-glucan.
See: 1,4-alpha-d-glucan branching enzyme.
Synonym: oligoglucan-branching glycosyltransferase.
(05 Mar 2000)
1,4-alpha-glucan 6-alpha-glucosyltransferase <enzyme> From aspergillus niger and oryzae
Registry number: EC 2.4.1.24
(26 Jun 1999)
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid <chemical> A stable prostaglandin endoperoxide analog which serves as a thromboxane mimetic. Its actions include mimicking the hydro-osmotic effect of vasopressin and activation of phospholipase c.
Pharmacological action: vasoconstrictor agents.
Chemical name: 5-Heptenoic Acid, 7-(6-(3-Hydroxy-1-Ocentyl)-2-Oxabicyclo(2.2.1)hept-5-yl)-, (1R-(1alpha,4alpha,5 beta(Z),6alpha(1E,3S*)))-
(12 Dec 1998)
5 alpha-3 alpha-hydroxysteroid dehydrogenase <enzyme> Androsterone can be substrate
Registry number: EC 1.1.1.50
Synonym: 3 alpha-hydroxysteroid dehydrogenase, 3 alpha-hydroxysteroid oxidoreductase, 3 oc-hydroxysteroid dehydrogenase
(26 Jun 1999)
5 alpha-androstane-3 beta,17 beta-diol 6 alpha-hydroxylase <enzyme> Requires NADPH, found in rat prostatic microsomes
Registry number: EC 1.14.13.-
Synonym: artdl 6 alpha-hydroxylase
(26 Jun 1999)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • orientation
    Áöµµ
  • consumer orientation
    (¸¶ÄÉÆÃ)¼ÒºñÀÚ ÁöÇâ
  • orientation
    µ¿ÂÊÀ¸·Î ÇâÇÏ°Ô ÇÔ;¹æÀ§;ŵµ ½ÃÁ¤;(½ÅÀÔ»ý µîÀÇ) Áöµµ
  • alpha
    ¾ËÆÄ
  • alpha
    ±×¸®½ºÀÚ¸ðÀÇ Ã¹Â°±ÛÀÚ
  • alpha particle
    ¾ËÆÄÀÔÀÚ
  • alpha plus
    ÃÖ°í±ÞÀÇ
  • alpha rays
    ¾ËÆÄ¼±
  • alpha rhythm
    (³úÆÄÀÇ)¾ËÆÄ¸®µë
  • alpha test
    Áö´ÉÅ×½ºÆ®
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á